Profile
ORCID iD: 0000-0001-5316-9115
Lucy Norling graduated with a Masters in Research and PhD from the William Harvey Research Institute, Queen Mary University of London in 2008. Her research focused on galectin-1; an endogenous regulator of inflammatory resolution. Dr. Norling was then awarded a 3 year Arthritis Research UK Foundation Fellowship to study the generation and bioactions of novel lipid mediators derived from omega-3 fatty acids and spent two years training at Harvard Medical School, Boston, with the mentorship of Professor Charles Serhan.
In 2012 Dr Norling attained a 5 year Arthritis Research UK Career Development Fellowship to investigate the protective actions of omega-3 fatty acid derived specialized pro-resolving lipid mediators (SPM) in inflammatory arthritis. SPM provide a molecular mechanism for the beneficial effects of fish oil supplementation in patients with arthritis, and offer novel therapeutic approaches to treat inflammatory diseases.
In 2019 Dr Norling was awarded a 5 year Versus Arthritis Senior Fellowship entitled “Reprogramming Resolution in the Arthritic Joint”. Her current research aims to determine whether inflammatory joint diseases persist due to an inadequate synthesis of SPM and explores how SPM protect and repair joint tissue.
Research
Group members
Hannah Law, Silvia Oggero, Shani Austin-Williams, Chiara Cecconello, Michele Padaovan.
Summary
Our understanding of how the inflammatory process is terminated has evolved, with the appreciation that protective mediators actively resolve inflammation. The discovery of omega-3 fatty acid derived specialized pro-resolving lipid mediators (SPM) provides a molecular mechanism for the beneficial effects of fish oil supplementation in patients with arthritis, and offer novel therapeutic approaches to treat inflammatory diseases. Supported by my Foundation Fellowship, I demonstrated that SPM inhibit PMN-endothelial interactions, dampen acute inflammation, and help fight infection. During my Career Development Fellowship I investigated the bioactions of SPM in experimental arthritis and found that resolvin D1 limits joint leukocyte infiltration, arthritis severity and protected from cartilage damage. We also determined that production of specific SPM including resolvin D3 is dysregulated in experimental arthritis, and that local SPM within murine joints can be modulated by omega-3 dietary supplementation.
There is a clear need to develop new innovative therapeutic agents for arthritis that can both reduce the inflammation that drives disease AND initiate tissue repair and regeneration. With the support of a Versus Arthritis Senior Fellowship I aim to establish how SPM reprogram innate immune cells and stromal cells within the joint tissue to switch on repair mechanisms that temper the aggressive and inappropriate behaviour of cells within the joint tissue to ultimately protect the cartilage from erosion. The overarching goal of our research is to establish novel leads for the restoration of joint function to ultimately limit disability and improve the lives of patients with arthritis.
